Technology Innovation Institute’s Secure Systems Research Centre in Abu Dhabi Announces Launch of First Motion Capture Facility Outside United States
8.9.2021 15:29:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) is pioneering a first-in-the-region Motion Capture (MOCAP) facility. Outside of the United States, SSRC’s unique MOCAP facility at its Masdar City premises, will enable the testing of Unmanned Aerial Systems (UAS) or drones in an augmented reality (AR) or mixed reality environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005700/en/
Dr Shreekant (Ticky) Thakkar, Chief Researcher, Secure Systems Research Centre, Technology Innovation Institute (Photo: AETOSWire)
The MOCAP facility will allow SSRC to simulate flying through the city of Abu Dhabi and enable high-precision ground truth to conduct sophisticated experiments as well as virtual, augmented and mixed reality testing. The ability to simulate virtual camera images and sensors facilitates testing in environments that are too large, too dangerous, or too time consuming to construct in reality.
The high-quality motion capture system proposed for Abu Dhabi will be able to conduct passive or active tracking and enhance the communication, navigation, command, and control capabilities achieved to date. SSRC is shaping this facility in line with its ongoing collaboration with US-based Purdue University that holds the distinction for the largest indoor motion capture facility in the world.
Speaking on the breakthrough facility that will allow the modelling and operation of a cloud-based secure autonomous system of drones - as opposed to just autonomous drones - in this environment, Dr Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “This is a start – an ambitious one – and we are confident we will be able to arrive at technologies that could limit malicious cyber-attacks as our reliance on drones continues to increase every day. They are integral to life today – from delivering valuable organs at a hospital to conducting surveillance of high-security zones, or dispersing seeds over a field or even completing grocery deliveries.
“This unique testing facility will be leveraged by various lab groups and allow us to conduct experiments on a broad range of Unmanned Aerial Systems of various sizes while the state-of-the-art high-resolution cameras track small objects in the surrounding environment. Our aim at SSRC is to develop breakthrough security solutions to safeguard systems that may be vulnerable, such as unsecure drone systems which may pose various threats to organisational or even individual privacy and safety. Therefore, it’s essential to make drone platforms more resilient and secure.”
On the construction of the new facility, James Goppert, Managing Director of the Purdue UAS Research and Test Facility said: “Autonomous drones are already playing a key part in package delivery and infrastructure inspection. As smart cities evolve, it will be critical to ensure the safe operation of drones in an urban setting. This facility is particularly suited to the task of bringing algorithms for the security of drones from simulation to real world application by allowing a gradual transition of scenario elements from pure simulation, to virtual, to real-world.”
The testing facility will be used by both the Secure Systems Research Centre and TII’s Autonomous Robotics Research Centre to carry out experiments on a range of vehicles. As a shared space, the Motion Capture facility can accommodate micro UAS weighing less than 10 g to large UAS that are as heavy as 1,000 kg and factor in different types of UAS from multirotor to helicopters to vertical takeoff and landing vehicles (VTOLs) to fixed wing craft.
For information on Technology Innovation Institute, visit www.tii.ae
For information on Secure Systems Research Centre, visit https://securesystems.tii.ae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005700/en/
Contact information
Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu
Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release
Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
